The resistance to anti-angiogenic treatment often occurs through the activation of alternative VEGF-independent signaling pathways such as recruitment of bone marrow-derived pro-angiogenic cells in the tumor microenvironment and/or tumor cells reprogramming into a more aggressive phenotype [10]. Here, VEGFA is linked to neoplasm.